Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis

AIM: The aim of this study was to determine the immunologic effects and safety of oral anti-CD3 in patients with ulcerative colitis (UC). METHODS: An open-label pilot study of orally delivered anti-CD3 was performed in patients with moderate-to-severe UC. The primary end points were changes in immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Boden, Elisa K, Canavan, James B, Moran, Christopher J, McCann, Katelyn, Dunn, William A, Farraye, Francis A, Ananthakrishnan, Ashwin N, Yajnik, Vijay, Gandhi, Roopali, Nguyen, Deanna D, Bhan, Atul K, Weiner, Howard L, Korzenik, Joshua R, Snapper, Scott B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690423/
https://www.ncbi.nlm.nih.gov/pubmed/31423487
http://dx.doi.org/10.1093/crocol/otz009
Descripción
Sumario:AIM: The aim of this study was to determine the immunologic effects and safety of oral anti-CD3 in patients with ulcerative colitis (UC). METHODS: An open-label pilot study of orally delivered anti-CD3 was performed in patients with moderate-to-severe UC. The primary end points were changes in immunologic parameters and evaluation for safety. RESULTS: Six subjects received oral OKT3. Biologic effects of oral anti-CD3 included significantly increased proliferation in response to anti-CD3 and anti-inflammatory gene expression profile in peripheral blood mononuclear cells. No serious treatment-related adverse events occurred. CONCLUSION: Orally delivered anti-CD3 resulted in immunologic changes in patients with UC.

Ejemplares similares